




MEDICINAL PRODUCTS 2020



MyMD Pharmaceuticals Inc.
Rank 18 of 52





RealRate

MEDICINAL PRODUCTS 2020

MyMD Pharmaceuticals Inc. Rank 18 of 52



The relative strengths and weaknesses of MyMD Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MyMD Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 122% points. The greatest weakness of MyMD Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 64%, being 68% points above the market average of -4.3%.

Input Variable	Value in 1000 USD
Assets, Current	10,311
Assets, Non-Current	574
General and Administrative Expense	5,065
Goodwill	170
Liabilities, Current	1,530
Liabilities, Non-Current	0
Other Assets	-204
Other Compr. Net Income	44
Other Expenses	181
Other Liabilities	0
Other Net Income	-58
Other Revenues	1,577
Property, Plant and Equipment, Net	34
Research and Development	277

Output Variable	Value in 1000 USD
Liabilities	1,530
Assets	10,885
Expenses	5,523
Revenues	1,577
Stockholders Equity	9,355
Net Income	-4,004
Comprehensive Net Income	-3,982
Economic Capital Ratio	64%